Peter Attia examines the failure of current prostate cancer screening guidelines, linking the decline in PSA testing to a rise in advanced and metastatic diagnoses. He explains how tracking PSA trends over time, combined with modern tools like MRI, PSA density, and improved biopsy techniques, can reduce unnecessary procedures while catching aggressive cancers earlier. The episode also covers active surveillance for low-risk cases and critiques the flawed PLCO trial that fueled anti-screening guidelines. Attia makes the case that regular, thoughtful PSA screening is essential to eliminating prostate cancer mortality.
This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.
Highlights
•
Current PSA screening guidelines are failing men02:30
Despite the availability of screening tools, advanced and metastatic prostate cancer diagnoses are rising because current PSA guidelines discourage routine testing.
Active surveillance avoids overtreatment of low-risk cancers25:30
For men with low-grade prostate cancer, active surveillance—regular monitoring with PSA, MRI, and repeat biopsies—is a safe alternative to immediate treatment.